Spotlight on immuno-oncology

The field of immuno-oncology is continuing to evolve at a fast rate. Our latest Spotlight takes a look at advances in the immuno-oncology field. Topics covered in this Spotlight will include combination therapies, the most recent immunotherapy advances, such as vaccines, and more. These topics will be explored via the latest immuno-oncology news, peer-reviewed journal articles and expert opinions.

 

Read more

 


Spotlight on prevention and screening

As the field of oncology continues to evolve, a major focus has become prevention and screening. Join us over the coming weeks on Oncology central as we take a look at the latest applications, challenges and the future of prevention and screening. In this Spotlight, we will cover topics such as biomarkers, liquid biopsies, the importance of educating clinicians on prevention and screening methods and more. This will be explored through features including peer-reviewed journal articles, the latest news and viewpoints from key opinion leaders in the form of Editorials and interviews.

 

Read more



Spotlight on precision medicine

Over the last decade, precision medicine has taken leaps forward, with projects such as the Precision Medicine Initiative, All of Us and the Human Cancer Models Initiative driving the development of new technologies to improve the diagnosis and treatment of diseases such as cancer. In this Spotlight we will pose the question; what resources do we require to achieve precision medicine in oncology and what challenges remain in this field? This will be explored through peer-reviewed journal articles, webinars, a panel discussion and viewpoints from key opinion leaders.

Read more


Spotlight on immuno-oncology

Immunotherapy is a huge area within oncology, which is having a significant impact on the way patients with certain malignancies are being treated. Combination therapies continue to show promise and other novel checkpoint inhibitors have led the field into an ever-increasing number of possible treatments. However, there are still numerous hurdles that need to be overcome to make this treatment modality an option for more treatment cancer types. In this Spotlight we will explore the current status of immunotherapy in the clinic.

 

Read more


Spotlight on tumor mutation burden

We have witnessed great advancements for cancer over the past few years, namely immunotherapy. Despite this success, the use of these drugs remains imprecise, with a limited ability to identify patients who will benefit from treatment. Tumor mutational burden (TMB) is promising as a predictive biomarker and could potentially lead the way for immuno-oncology to enter an era of precision medicine.

 

Read more



Spotlight on biosimilars in oncology

Over the coming weeks on Oncology Central we will be carrying out a Spotlight event exploring the field of biosimilars in oncology. Join us as we look further into their development, evaluate the potential benefits alongside regulatory challenges and see whether there are sufficient resources available to clinicians who are considering adopting biosimilars.

Read more



Spotlight on interventional oncology

Much of the available literature discussing the topic defines interventional oncology as the fourth pillar of cancer therapy, where it stands alongside medical, surgical and radiation oncology. Over the coming weeks on Oncology Central we will be carrying out a Spotlight event looking further into the field of interventional oncology. This Spotlight will take an overarching view and aim to review this discipline from benchside to bedside.

Read more



Spotlight on cancer and the immune system

Cancer immunotherapy is arguably one of the biggest developments and one of hottest topic within oncology. This Spotlight reviews the intricacies of how cancer cells and immune cells interact, look at the escape mechanisms that cancers employ to evade an antitumor immune response and explore the story behind some of the novel immunotherapy agents that have been developed to reverse this immune evasion.

Read more



Spotlight on circulating tumor cells

As has been proven, cancer does not simply consist of one type of cell; rather tumors can be made up of a heterogeneous collection of cells with varying phenotypes. It has been proposed that only a small subpopulation of the cells making up a tumor hold any tumorigenic potential – namely cancer stem cells (CSCs). The CSC model proposes that these cells renew and sustain the tumor in a background of nontumorigenic cells, driving therapy resistance, recurrence and enabling metastatic spread.

Read more



Spotlight on cancer stem cells

As has been proven, cancer does not simply consist of one type of cell; rather tumors can be made up of a heterogeneous collection of cells with varying phenotypes. It has been proposed that only a small subpopulation of the cells making up a tumor hold any tumorigenic potential – namely cancer stem cells (CSCs). The CSC model proposes that these cells renew and sustain the tumor in a background of nontumorigenic cells, driving therapy resistance, recurrence and enabling metastatic spread.

Read more